Table 1 General characteristics
No Match | Match | |||||||
|---|---|---|---|---|---|---|---|---|
Total population n= 505 | Rivaroxaban n= 220 | Warfarin n= 285 | p value | Total population n= 418 | Rivaroxaban n= 209 | Warfarin n= 209 | p value | |
Age years, m(SD) | 59.9 (19.41) | 60.4 (18.94) | 59.5 (19.79) | 0.64 | 60.8 (19.21) | 60 (18.59) | 61.6 (19.82) | 0.37 |
Male, n(%) | 283 (56) | 118 (53.6) | 165 (57.9) | 0.34 | 242 (57.9) | 116 (55.5) | 126 (60.3) | 0.32 |
Comorbidities, n (%) | ||||||||
Arterial hypertension | 201 (39.8) | 86 (39.1) | 115 (40.4) | 0.77 | 170 (40.7) | 81 (38.8) | 89 (42.6) | 0.43 |
Congestive heart failure | 28 (5.5) | 12 (5.5) | 16 (5.6) | 0.94 | 24 (5.7) | 12 (5.7) | 12 (5.7) | 1.00 |
Acute myocardial infarction | 5 (1) | 2 (0.9) | 3 (1.1) | 0.87 | 5 (1.2) | 2 (1) | 3 (1.4) | 0.65 |
Atrial fibrillation | 18 (3.6) | 6 (2.7) | 12 (4.2) | 0.37 | 13 (3.1) | 5 (2.4) | 8 (3.8) | 0.40 |
CE History | 44 (8.7) | 17 (7.7) | 27 (9.5) | 0.49 | 31 (7.4) | 15 (7.2) | 16 (7.7) | 0.85 |
Dementia | 10 (2) | 8 (3.6) | 2 (0.7) | 0.02 | 6 (1.4) | 4 (1.9) | 2 (1) | 0.41 |
COPD | 45 (8.9) | 18 (8.2) | 27 (9.5) | 0.61 | 35 (8.4) | 17 (8.1) | 18 (8.6) | 0.86 |
Diabetes | 57 (11.3) | 23 (10.5) | 34 (11.9) | 0.60 | 52 (12.4) | 23 (11) | 29 (13.9) | 0.37 |
Obesity | 24 (4.8) | 11 (5) | 13 (4.6) | 0.82 | 22 (5.3) | 10 (4.8) | 12 (5.7) | 0.66 |
Cancer | 39 (7.7) | 19 (8.6) | 20 (7) | 0.50 | 35 (8.4) | 19 (9.1) | 16 (7.7) | 0.60 |
Metástasis | 13 (2.6) | 7 (3.2) | 6 (2.1) | 0.45 | 13 (3.1) | 7 (3.3) | 6 (2.9) | 0.78 |
Active cancer in the last year | 18 (3.6) | 10 (4.5) | 8 (2.8) | 0.30 | 18 (4.3) | 10 (4.8) | 8 (3.8) | 0.63 |
Surgery in the last 4 weeks, n (%) | 78 (15.4) | 40 (18.2) | 38 (13.3) | 0.13 | 66 (15.8) | 37 (17.7) | 29 (13.9) | 0.28 |
Knee replacement, n (%) | 18 (3.6) | 9 (4.1) | 9 (3.2) | 0.57 | 17 (4.1) | 9 (4.3) | 8 (3.8) | 0.80 |
PE history, n (%) | 23 (4.6) | 6 (2.7) | 17 (6) | 0.08 | 12 (2.9) | 6 (2.9) | 6 (2.9) | 1.00 |
DVT history, n (%) | 96 (19) | 30 (13.6) | 66 (23.2) | 0.01 | 63 (15.1) | 30 (14.4) | 33 (15.8) | 0.68 |